ABSTRACT
Background Influenza controlled human infection model (CHIM) studies can advance development of vaccines and therapeutics. Our objective was to evaluate the associations between baseline challenge virus-specific hemagglutination inhibition (HAI) and microneutralization (MN) titers and subsequent symptomatic influenza virus infection.
Methods We enrolled healthy adults aged 18 through 49 years in a multisite CHIM study using influenza A/Bethesda/MM2/H1N1, an A/California/04/2009/H1N1pdm-like virus (NCT04044352). We excluded persons vaccinated against influenza within the previous six months. We collected serial safety labs, serum for HAI and MN, and nasopharyngeal swabs for RT-PCR testing. Analyses used the putative seroprotective titer of ≥40 for HAI and MN. The primary clinical outcome was mild-to-moderate influenza disease (MMID), defined as ≥1 post-challenge positive qualitative RT-PCR test with a qualifying symptom/clinical finding.
Findings Of 76 participants given influenza virus challenge, 54 (71.1%) experienced MMID. Clinical illness post-challenge was generally very mild. MMID attack rates among participants with baseline titers ≥40 by HAI and MN were 64.9% and 67.9%, respectively, while MMID attack rates among participants with baseline titers <40 by HAI and MN were 76.9% and 78.3%, respectively. The estimated odds of developing MMID decreased by 19% (odds ratio=0.81; 95% CI: 0.62, 1.06; p=0.126) for every two-fold increase in baseline HAI. There were no deaths, serious adverse events, or other significant adverse events.
Interpretation In a multi-site influenza CHIM study, we assured the safety of our participants and achieved a 71.1% attack rate of MMID. High baseline HAI and MN were associated with protection from illness.
Competing Interest Statement
Justin R. Ortiz reports grants to his institution from National Science Foundation, Bill & Melinda Gates Foundation, Pfizer, National Institutes of Health, and World Health Organization outside the submitted work. He reports receiving consulting fees from Putnam outside the submitted work, and participation on an advisory board for Pfizer, Seqirus, and Moderna outside the submitted work. David I. Bernstein reports receiving consulting fees from Rational vaccines and participation on an advisory board with Moderna and Dynavax outside the submitted work. Daniel F. Hoft reports no interests. Chris W. Woods reports grants to his institution from Janssen and Aztra Zeneca outside the submitted work. Micah T. McClain reports grants to his institution from National Institutes of Health outside the submitted work. Sharon Frey reports no interests. Rebecca C. Brady reports no interests. Chris Bryant reports no interests. Ashley Wegel reports no interests. Robert W Frenck Jr. reports grants to his institution from Pfizer outside the submitted work. He reports receiving clinical trial support from Pfizer. Emmanuel Walter reports grants to his institution from Moderna, Pfizer, Seqirus, and Iliad Biotechnologies. He reports receiving consulting fees from Iliad Biotechnologies and participation on the Vaxcyte advisory board. Getahun Abate reports no interests. Sarah R. Williams reports no interests. Robert L. Atmar reports no interests. Wendy A. Keitel reports grants to her institution from Leidos. outside the submitted work. She reports receiving clinical trial support from Pfizer. She reports receiving a subcontract from Leidos and participating on an advisory board with the National Institutes of Health. Nadine Rouphael reports grants to her institution from Merck Sanofi Pasteur, Quidel, Pfizer, and Lilly outside the submitted work. Mathew J. Memoli reports no interests. Paul C. Roberts reports no interests. Mamodikoe K. Makhene reports no interests. Kathleen M. Neuzil reports no interests.
Clinical Trial
NCT04044352
Funding Statement
This project has been funded in whole or part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contracts: HHSN272201300016I (Cincinnati Children's Hospital Medical Center); 75N93021C00012 (The Emmes Company); HHSN272201300022I (University of Maryland, Baltimore); HHSN2722013000017I (Duke University); HHSN272201300018I (Emory University); HHSN272200800003C (St. Louis University); and HHSN272201300015I (Baylor College of Medicine). Partial support of the University of Maryland, Baltimore, Institute for Clinical & Translational Research (ICTR) was provided by the National Center for Advancing Translational Sciences (NCATS) Clinical Translational Science Award (CTSA) grant number 1UL1TR003098.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Maryland Baltimore Institutional Review Board of University of Maryland School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: jortiz{at}som.umaryland.edu, david.bernstein{at}cchmc.org, daniel.hoftdf{at}health.slu.edu, chris.woods{at}duke.edu, micah.mcclain{at}duke.edu, sharon.frey{at}health.slu.edu, Rebecca.brady{at}cchmc.org, cbryant{at}emmes.com, awegel{at}emmes.com, robert.frenck{at}cchmc.org, chip.walter{at}duke.edu, getahun.abate{at}health.slu.edu, Sarah.Williams{at}som.umaryland.edu., ratmar{at}bcm.edu, wkeitel{at}bcm.edu, nroupha{at}emory.edu, memolim{at}niaid.nih.gov, mmakhene{at}niaid.nih.gov, paul.roberts{at}nih.gov, kneuzil{at}som.umaryland.edu
For the Influenza Controlled Human Infection Study Group Members (listed in supplement)
Data Availability
Data to be made available as widely as possible while safeguarding the privacy of participants, and protecting confidential and proprietary data.
